Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease

1

Metabolic dysfunction-associated steatotic liver disease (MASLD) progresses from hepatic steatosis to cirrhosis and is linked to obesity and type 2 diabetes.
2

Insulin-like growth factor binding proteins (IGFBPs) play significant roles in MASLD through both IGF-dependent and IGF-independent mechanisms.
3

IGFBP1 and IGFBP2 promote metabolic protection by enhancing lipid oxidation and insulin sensitivity in MASLD.
4

IGFBP3 and IGFBP5 have dual roles, restraining lipogenesis early but promoting injury and fibrosis later in MASLD.
5

IGFBP7 is a pathogenic modulator that impairs insulin signaling and drives fibrosis, while IGFBP4 and IGFBP6 are less characterized.

1